Erste Group Bank Has Strong Outlook for TMO FY2027 Earnings

Key Points

• Erste Group Bank raised its FY2027 EPS estimate for Thermo Fisher Scientific to $27.51 from $27.44, well above the current consensus estimate of $25.13.
• Thermo Fisher recently exceeded quarterly expectations, reporting $6.03 EPS and $11.99 billion in revenue; revenue rose 10.5% year over year, and management provided FY2026 EPS guidance of $24.93–$25.33.
• Analyst sentiment remains broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $638.67, while institutional investors own 89.23% of shares.

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Erste Group Bank boosted their FY2027 earnings per share estimates for shares of Thermo Fisher Scientific in a note issued to investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the medical research company will post earnings of $27.51 per share for the year, up from their prior estimate of $27.44. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $25.13 per share.

Other research analysts also recently issued reports about the stock. BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a "market perform" rating in a report on Wednesday, September 9th. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a report on Monday, July 6th. UBS Group upgraded Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and increased their target price for the stock from $540.00 to $730.00 in a research report on Tuesday, September 8th. HSBC upgraded Thermo Fisher Scientific from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 1st. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $730.00 price target on shares of Thermo Fisher Scientific in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average price target of $638.67.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $661.65 on Tuesday. The company's 50 day moving average is $629.14 and its 200-day moving average is $543.01. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $694.33. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a market cap of $244.64 billion, a P/E ratio of 35.59, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company's revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS.

Insider Activity

In related news, CAO Joseph R. Holmes sold 420 shares of the company's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 275 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 73,768 shares of company stock valued at $44,122,820. Corporate insiders own 0.33% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TMO. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $15,501,867,000. Corient Private Wealth LP bought a new position in Thermo Fisher Scientific in the 2nd quarter worth $382,547,000. Bank of New York Mellon Corp purchased a new position in Thermo Fisher Scientific during the second quarter valued at $1,974,561,000. Bank of America Corp DE bought a new stake in Thermo Fisher Scientific during the second quarter valued at about $1,952,930,000. Finally, Auto Owners Insurance Co grew its holdings in Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company's stock valued at $1,406,844,000 after purchasing an additional 2,423,706 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.